LVHB Innovator Lunt Low VolHigh Beta Tactical ETF

Innovator Capital Management, LLC (Innovator) announced today the Innovator IBD® 50 ETF (NYSE:FFTY) celebrated its 3-year anniversary on April 9th, 2018. As of April 30th, 2018 the fund earned a Morningstar 4-Star Rating out of 18 ETFs based on risk-adjusted returns for the 3 year and Overall period. FFTY, which is categorized by Morningstar as a Mid-Cap Growth ETF, has outperformed the Morningstar Mid Growth Index by over 2.4% per year1 since it incepted on April 9, 2015. The Fund’s assets increased from $38 million in May 2017 to more than $352 million as of April 30th, 2018.

The Innovator IBD 50 ETF (FFTY) provides exposure to a tactical, high-conviction portfolio of the 50 top-ranked growth stocks according to Investor’s Business Daily’s (IBD®) CAN SLIM Investing System.

“We are thrilled to celebrate the Innovator IBD 50 ETF three-year track record and 4-Star Morningstar Rating,” said Bruce Bond, Chief Executive Officer of Innovator. “Investor’s Business Daily has garnered a strong reputation and wide investor following for identifying high-quality emerging growth companies. We look forward to partnering on additional strategies in the future.”  

“The IBD 50 has a long record of outperformance and long-term investors can use this as an opportunity to dollar cost average into the strategy,” added Chris Gessel, Chief Content Officer of IBD.

Innovator IBD® 50 ETF Performance as of 3/31/2018
	YTD	1 Year	3 Year	5 Year	Inception
ETF NAV	0.39%	31.22%	-	-	10.15%
ETF Closing Price	0.42%	31.40%	-	-	10.19%
Morningstar Mid Growth Index	3.36%	20.82%	-	-	7.46%
S&P 500 Index	-0.76%	14.07%	-	-	10.59%

Fund inception is 4/9/2015. FFTY has a gross expense ratio of 1.03% and a net expense ratio of 0.80%, which represents a contractual fee waiver in effect through 5/9/19. Performance quoted represents past performance, which is no guarantee of future results. Investment returns and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. One cannot invest directly in an index. Visit innovatoretfs.com for current month-end performance.

The Innovator IBD® 50 ETF tracks the IBD 50 Index. The CAN SLIM methodology governing the stock selection of the Index incorporates both fundamental and technical analysis, evaluating current and annual earnings, new products, service or management, stock price performance, leadership, institutional ownership, and the overall market. The Index is reconstituted and rebalanced on a weekly basis and weighted based on the strength of component ratings to maintain the 50 leading growth stocks from a universe of over 7,000 names.

IBD 50 Rank Weighted List performance

Since List Inception (4.11.2003)2	Annualized Return (%)	Std. Dev.
IBD 50 Rank Weighted List	21.22%	20.13%
S&P 500 Index	9.95%	13.27%

Source: IBD as of March 31, 2018. Performance quoted represents past performance, which is no guarantee of future results.

Focusing on industry-leading companies that are generating outstanding profit growth, significant sales increases, wide profit margins, and high return on equity, combined with institutional sponsorship, the IBD 50 CAN SLIM selection methodology has a history of picking the most dynamic growth stocks that regularly outpace the broad market, regardless of market cap, sector and geography.

About Innovator Capital Management, LLCInnovator Capital Management, LLC is an SEC registered investment advisor (RIA) based in Wheaton, IL. Formed in 2014, the firm is currently headed by ETF visionaries Bruce Bond and John Southard, founders of one of the largest ETF providers in the world. Innovation is our hallmark and acts as a guide to our company principles. Innovator is committed to helping investors better control their financial outcomes by providing investment opportunities they never considered or thought possible.

About Investor’s Business DailyInvestor’s Business Daily is a leading financial news and research organization recognized for providing stock screens, comparative performance ratings, and unique commentary helping investors zero in on top performing growth stocks. IBD® offers individual and professional investors a comprehensive lineup of print and online products, all based on a powerful investing system that has dramatically outperformed the S&P 500. IBD® was founded by William J. O'Neil, who also originated CAN SLIM.

Media ContactBill Conboy+1 (303) 415-2290bill@bccapitalpartners.com                       

1 Source: Bloomberg L.P., data from April 9, 2015 to April 9, 2018.

2 The IBD List has been historically published since 4/11/2003. On 11/3/2017 it was formally codified in the IBD 50 Index.

Investing involves risks. Principal loss is possible. ETFs face numerous market trading risks, including the potential lack of an active market for Fund shares, losses from trading in secondary markets, periods of high volatility and disruption in the creation/redemption process of the Fund. Unlike mutual funds, ETFs may trade at a premium or discount to their net asset value. ETFs are bought and sold at market price and not individually redeemed from the fund. Brokerage commissions will reduce returns. It is not possible to invest directly in an index. The “IBD®” mark and logo have been licensed to the Adviser by Investor’s Business Daily, Inc. (IBD) for use in connection with the Fund under certain circumstances. The Fund is not sponsored, endorsed or sold by IBD. IBD makes no representation regarding the advisability of investing in the Fund. Investor’s Business Daily® mark and associated logos are used with permission by IBD.

The Morningstar RatingTM for funds, or “star rating”, is calculated for managed products (including mutual funds, variable annuity and variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) from 1 to 5 stars based on how well they've performed (after adjusting for risk and accounting for sales charges) in comparison to similar funds and ETFs. Ratings are objective, based entirely on a mathematical evaluation of past performance. Past performance is no guarantee of future results. Ratings reflect fee waivers in effect; in their absence, ratings may have been lower. The Morningstar RatingTM for funds, or “star rating”, is calculated for managed products with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.

The Fund’s investment objectives, risks, charges and expenses should be considered before investing. The prospectus contains this and other important information, and may be obtained at innovatoretfs.com. Read it carefully before investing. Innovator ETFs are distributed by Foreside Fund Services, LLC.

Copyright © 2018 Innovator Capital Management, LLC.800.208.5212